94 related articles for article (PubMed ID: 20829635)
1. No influence of DTNBP1 polymorphisms on the response to aripiprazole.
Pae CU; Chiesa A; Mandelli L; Serretti A
Neuropsychobiology; 2010; 62(4):245-9. PubMed ID: 20829635
[TBL] [Abstract][Full Text] [Related]
2. No influence of FAT polymorphisms in response to aripiprazole.
Pae CU; Chiesa A; Mandelli L; De Ronchi D; Serretti A
J Hum Genet; 2010 Jan; 55(1):32-6. PubMed ID: 19893579
[TBL] [Abstract][Full Text] [Related]
3. DTNBP1 haplotype influences baseline assessment scores of schizophrenic in-patients.
Pae CU; Drago A; Kim JJ; Patkar AA; Jun TY; Lee C; Mandelli L; De Ronchi D; Paik IH; Serretti A
Neurosci Lett; 2008 Aug; 440(2):150-4. PubMed ID: 18562100
[TBL] [Abstract][Full Text] [Related]
4. Influence of TAAR6 polymorphisms on response to aripiprazole.
Serretti A; Pae CU; Chiesa A; Mandelli L; De Ronchi D
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug; 33(5):822-6. PubMed ID: 19345712
[TBL] [Abstract][Full Text] [Related]
5. Influence of DAOA gene variants on antipsychotic response after switch to aripiprazole.
Pae CU; Chiesa A; Serretti A
Psychiatry Res; 2010 Jul; 178(2):430-2. PubMed ID: 20471098
[TBL] [Abstract][Full Text] [Related]
6. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole.
Kwon JS; Kim E; Kang DH; Choi JS; Yu KS; Jang IJ; Shin SG;
Eur Neuropsychopharmacol; 2008 Dec; 18(12):897-907. PubMed ID: 18786813
[TBL] [Abstract][Full Text] [Related]
7. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
Lin CH; Lin SH; Jang FL
J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
[TBL] [Abstract][Full Text] [Related]
8. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study.
Mitsonis CI; Dimopoulos NP; Mitropoulos PA; Kararizou EG; Katsa AN; Tsakiris FE; Katsanou MN
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):373-7. PubMed ID: 17092620
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
[TBL] [Abstract][Full Text] [Related]
10. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
[TBL] [Abstract][Full Text] [Related]
11. Trial of aripiprazole in the treatment of first-episode schizophrenia.
Lee HY; Ham BJ; Kang RH; Paik JW; Hahn SW; Lee MS; Lee MS
Psychiatry Clin Neurosci; 2010 Feb; 64(1):38-43. PubMed ID: 20416024
[TBL] [Abstract][Full Text] [Related]
12. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
[TBL] [Abstract][Full Text] [Related]
13. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
14. Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy.
Pae CU; Serretti A; Mandelli L; De Ronchi D; Patkar AA; Jun TY; Kim JJ; Lee CU; Lee SJ; Lee C; Paik IH
Pharmacogenet Genomics; 2007 Jan; 17(1):69-75. PubMed ID: 17264804
[TBL] [Abstract][Full Text] [Related]
15. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
Miura I; Takeuchi S; Katsumi A; Mori A; Kanno K; Yang Q; Mashiko H; Numata Y; Niwa S
J Clin Psychopharmacol; 2012 Feb; 32(1):106-9. PubMed ID: 22198450
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Bae KY; Yang SJ; Yoon JS
Clin Neuropharmacol; 2010 May; 33(3):121-5. PubMed ID: 20502130
[TBL] [Abstract][Full Text] [Related]
17. Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study.
Christensen AF; Poulsen J; Nielsen CT; Bork B; Christensen A; Christensen M
Acta Psychiatr Scand; 2006 Feb; 113(2):148-53. PubMed ID: 16423167
[TBL] [Abstract][Full Text] [Related]
18. Effect of 5-haplotype of dysbindin gene (DTNBP1) polymorphisms for the susceptibility to bipolar I disorder.
Pae CU; Serretti A; Mandelli L; Yu HS; Patkar AA; Lee CU; Lee SJ; Jun TY; Lee C; Paik IH; Kim JJ
Am J Med Genet B Neuropsychiatr Genet; 2007 Jul; 144B(5):701-3. PubMed ID: 17192893
[TBL] [Abstract][Full Text] [Related]
19. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study.
Pae CU; Serretti A; Chiesa A; Mandelli L; Lee C; Lee C; Kim J; De Ronchi D; Paik IH
Eur Neuropsychopharmacol; 2009 Aug; 19(8):562-70. PubMed ID: 19442491
[TBL] [Abstract][Full Text] [Related]
20. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
